UNSPSC 51101680: Quinfamide

This classification denotes an antiprotozoal agent with the molecular formula C16H13Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O1ZB1046R1, chemically known as 2-furoic acid ester with 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol but generally known as quinfamide, which bears US NIH Compound Identifier 71743. European Medicines Agency schedules Quinfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10215MIG. The term QUINFAMIDE is an International Non-Proprietary Name.

UNSPSC 51101680 Quinfamide, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The recent opportunities show instead that issuing bodies are soliciting naloxone, generic pharmaceuticals, over-the-counter products, and medical-supply procurement — none of which match the nominal scope of quinfamide, a specific pharmaceutical compound. The code shows little relevant recent activity directly tied to its stated product.

The sourced opportunities reflect broader pharmaceutical and medical-supply procurement across state health agencies, counties, and municipalities. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems, with annual volumes of 1,900 and 800 units respectively and quarterly deliveries. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription-fulfillment capabilities outside traditional PBM and GPO channels. The City of Tampa released an IFB (26P00145, due March 13, 2026) for medical and first-aid supplies serving the Fire Department Rescue Division, with an estimated contract value of $700,000, designated as a sheltered-market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers with an effective date of July 1, 2026. The code's nominal scope and the work actually being procured do not correspond; procurement activity under this code should be verified against the issuing body's intended product classification.